Central retinal vein occlusion
Conditions
Interventions
Western Medicine Group:Ranibizumab intravitreal injection
Joint Group:Quji Tongluo Decoction combined with Ranibizumab intravitreal injection
Traditional Chinese Medicine Group:Quji Tongluo Decoction
Sponsors
Eye Hospital China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 80 years regardless of gender. (2) The experimental group meets the Western medical diagnostic criteria for CRVO and the Traditional Chinese Medicine diagnostic criteria for phlegm-stasis syndrome. (3) Healthy control group participants should match the experimental group in age and gender with normal fundus examinations and no signs of retinal hemorrhage exudation or other abnormalities. (4) Able to cooperate in completing OCTA examinations. (5) First-time diagnosed cases in our hospital with symptom onset within the past 3 months and no prior drug or surgical treatment received. (6) Willing to participate in this clinical trial and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Intraocular pressure (IOP) measurement exceeding 21 mmHg at any time. (2) Concurrent ocular diseases causing refractive media opacity resulting in an OCTA signal index below 6. (3) Concurrent inflammatory diseases or fundus disorders including keratitis iridocyclitis retinal vasculitis retinal detachment diabetic retinopathy retinitis pigmentosa age-related macular degeneration etc. (4) Severe systemic diseases unstable vital signs such as acute infarction advanced-stage tumors acute-phase cerebral infarction etc. (5) Individuals with a bleeding tendency or those who have experienced severe bleeding within the past 3 months. (6) History of ocular trauma or surgery within the past 3 months. (7) Neurological or psychiatric disorders that hinder cooperation or unwillingness to cooperate. (8) Suspected or confirmed history of alcohol or drug abuse or long-term use of medications (including traditional Chinese medicine anticoagulants etc.) that may affect study outcomes as determined by the investigator. (9) Pregnant or breastfeeding women or those planning pregnancy in the near future. (10) Participation in other clinical trials within the past months or any other conditions deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vessel density of optic disc; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripapillary Retinal Nerve Fiber Layer Thickness;Optic Nerve Head Volume;Visual acuity;Vessel density of macula;Central Macular Thickness;Cup-to-Disc Ratio;Optic Disc Area;Intraocular pressure;Anterior Segment Examination;Fundus examination;Fundus Fluorescein Angiography;Comprehensive Hemorheology Panel;Coagulation function; | — |
Countries
China
Contacts
Public ContactLixuan
Eye Hospital China Academy of Chinese Medical Sciences
Outcome results
None listed